BiotechTube

Disodium pamidronate + Placebo

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Bone Disease, Metabolic

Conditions

Bone Disease, Metabolic

Trial Timeline

Dec 1, 2000 → Dec 1, 2003

NCT ID
NCT00657852

About Disodium pamidronate + Placebo

Disodium pamidronate + Placebo is a approved stage product being developed by Novartis for Bone Disease, Metabolic. The current trial status is completed. This product is registered under clinical trial identifier NCT00657852. Target conditions include Bone Disease, Metabolic.

What happened to similar drugs?

9 of 20 similar drugs in Bone Disease, Metabolic were approved

Approved (9) Terminated (1) Active (10)
🔄Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
🔄Arzoxifene + PlaceboEli LillyPhase 3
🔄TanezumabEli LillyPhase 3
🔄Anastrozole + TamoxifenAstraZenecaPhase 3
🔄zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplementsNovartisPhase 3
🔄Zoledronic acidNovartisPhase 3
🔄Zoledronic acid + LetrozoleNovartisPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00657852ApprovedCompleted

Competing Products

20 competing products in Bone Disease, Metabolic

See all competitors
ProductCompanyStageHype Score
Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
40
EnzalutamideAstellas PharmaPhase 2
35
EnzalutamideAstellas PharmaPhase 2
35
TacrolimusAstellas PharmaPhase 2
35
TacrolimusAstellas PharmaPhase 2
35
MerestinibEli LillyPhase 1
21
FORTEO + PlaceboEli LillyPhase 1
29
Arzoxifene + PlaceboEli LillyPhase 3
40
TanezumabEli LillyPhase 3
40
Anastrozole + TamoxifenAstraZenecaPhase 3
40
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplementsNovartisPhase 3
40
Zoledronic acidNovartisPhase 3
40
Zoledronic acid + LetrozoleNovartisPhase 3
40
Zoledronic acidNovartisPhase 3
40
NilotinibNovartisPhase 1
29
Reclast (ZOL446, zoledronic acid)NovartisApproved
43
Zoledronic acidNovartisPhase 3
32
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic AcidNovartisPhase 3
40
zoledronic acidNovartisPhase 1
29
Ruxolitinib continuous therapyNovartisPhase 2
39